Search Immortality Topics:

Page 11234..1020..»

Category Archives: Pharmacogenomics

April 16: Pharmacogenomics – National Human Genome …

PharmacogenomicsChoosing the right medication at the right dose for each patient April 16, 2018 Did you know … Continue reading

Posted in Pharmacogenomics | Comments Off on April 16: Pharmacogenomics – National Human Genome …

Omics – Wikipedia

The English-language neologism omics informally refers to a field of study in biology ending in -omics, such as genomics, proteomics or metabolomics. The related suffix -ome is used to address the objects of study of such fields, such as the genome, proteome or metabolome respectively Continue reading

Posted in Pharmacogenomics | Comments Off on Omics – Wikipedia

Ion AmpliSeq Designer

AmpliSeq On-Demand Panels: Coming up with different design combinations for a panel requires time and effort. And you guys are doing all the work I like the idea of ordering only the genes that I see more – Dr. William G Continue reading

Posted in Pharmacogenomics | Comments Off on Ion AmpliSeq Designer

Pharmacogenomics – NCPA

General Description, Overview, and Opportunities Pharmacogenomics has increasingly become an area of interest to clinicians because of the potential to tailor pharmacotherapy based on genetic variations in patients. Pharmacogenomics is one of the key aspects of personalized medicine, focusing on how an individual’s DNA affects the way they respond to medications Continue reading

Posted in Pharmacogenomics | Comments Off on Pharmacogenomics – NCPA

CYP2C9 – Wikipedia

Cytochrome P450 2C9 (abbreviated CYP2C9) is an enzyme that in humans is encoded by the CYP2C9 gene.[5][6] CYP2C9 is an important cytochrome P450 enzyme with a major role in the oxidation of both xenobiotic and endogenous compounds. CYP2C9 makes up about 18% of the cytochrome P450 protein in liver microsomes (data only for antifungal). Some 100 therapeutic drugs are metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and phenytoin and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, glipizide, and some nonsteroidal anti-inflammatory drugs. Continue reading

Posted in Pharmacogenomics | Comments Off on CYP2C9 – Wikipedia

Irinotecan – Wikipedia

IrinotecanClinical dataTrade namesCamptosar (US), Campto (EU), Onivyde (liposomal)AHFS/Drugs.comMonographMedlinePlusa608043Pregnancycategory O=C7OCC=6C(=O)N2C(c1nc5c(c(c1C2)CC)cc(OC(=O)N4CCC(N3CCCCC3)CC4)cc5)=C/C=6[[email protected]@]7(O)CC Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer and small cell lung cancer.[1] For colon cancer it is used either alone or with fluorouracil.[1] For small cell lung cancer it is used with cisplatin.[1] It is given by slow injection into a vein.[1] Common side effects include diarrhea, vomiting, bone marrow suppression, hair loss, shortness of breath, and fever.[1] Other severe side effects include blood clots, colon inflammation, and allergic reactions.[1] Those with two copies of the UGT1A1*28 gene variant are at higher risk for side effects.[1] Use during pregnancy can result in harm to the baby.[1] Irinotecan is in topoisomerase inhibitor family of medication.[2] It works by blocking topoisomerase 1 which results in DNA damage and cell death.[1] Irinotecan was approved for medical use in the United States in 1996.[1] It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] In the United Kingdom it is available as a generic medication and costs the NHS about 114.00 pounds per 100mg.[2] It is made from the natural compound camptothecin.[1] Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan. The regimen XELIRI consists of capecitabine and irinotecan.[4][5] The most significant adverse effects of irinotecan are severe diarrhea and extreme suppression of the immune system.[6] Irinotecan-associated diarrhea is severe and clinically significant, sometimes leading to severe dehydration requiring hospitalization or intensive care unit admission Continue reading

Posted in Pharmacogenomics | Comments Off on Irinotecan – Wikipedia